UAS
ACOR

United Asset Strategies’s Acorda Therapeutics ACOR Stock Holding History

United Asset Strategies’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,355
Closed -$20.8K – 248
2022
Q4 		$20.8K Hold
1,355
– – ﹤0.01% 223
2022
Q3 		$8K Hold
1,355
– – ﹤0.01% 209
2022
Q2 		$13K Hold
1,355
– – ﹤0.01% 203
2022
Q1 		$44K Hold
1,355
– – 0.01% 206
2021
Q4 		$65K Hold
1,355
– – 0.01% 205
2021
Q3 		$125K Hold
1,355
– – 0.02% 195
2021
Q2 		$129K Buy
+1,355
New +$119K 0.02% 196

Other funds holding ACOR

DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
DKP
Davidson Kempner Partners New York $5.16B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

United Asset Strategies's ACOR Position: Q1 2023 in Review

United Asset Strategies sold out of Acorda Therapeutics (ACOR) in Q1 2023, closing a stake of 1,355 shares — an estimated $20.8K sold.

United Asset Strategies first reported a position in ACOR in Q2 2021 and held it in 7 quarters. The position peaked at $129K in Q2 2021. 29 funds tracked by Wall St. Rank hold ACOR as of Q1 2023.

  • United Asset Strategies reported no remaining Acorda Therapeutics position as of Q1 2023 after selling out during the quarter.
  • United Asset Strategies sold 1,355 Acorda Therapeutics shares in Q1 2023, an estimated $20.8K.
  • United Asset Strategies first reported a position in Acorda Therapeutics in Q2 2021 and held it in 7 quarters.
  • United Asset Strategies's Acorda Therapeutics position peaked at $129K in Q2 2021.
  • 29 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2023.

Based on United Asset Strategies's 13F filing for Q1 2023, filed 25 Apr 2023.